MOVE-OK: A Pragmatic Trial To Determine the Benefit of Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT03835910
Collaborator
(none)
34
1
4
23.8
1.4

Study Details

Study Description

Brief Summary

Knee osteoarthritis (KOA) is one of the most common and disabling conditions among Veterans. Management of KOA is challenging as there are few effective treatments other than joint replacement. Importantly, low levels of physical activity in patients with knee problems might worsen pain and disability. This study aims to determine the feasibility of using methods to change behavior that use social incentives and promote physical activity through playing games and interacting with a web-based platform. The study will also evaluate an important and widely used treatment, namely corticosteroid injections. Participants will be randomized into one of 4 arms and will receive a different combination of social incentives and injections. The study will evaluate which approach is most effective at promoting physical activity and reducing pain and disability.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Social Incentives and Gamification to Promote Exercise
  • Procedure: Corticosteroid Injection given in A-B order
  • Behavioral: No Social Incentive applied
  • Procedure: Corticosteroid Injection given in B-A order
N/A

Detailed Description

Knee osteoarthritis (KOA) is one of the most prevalent and disabling conditions among Veterans and accounts for high morbidity and high costs for the VA. Management of KOA is challenging as there are few consistently effective treatments other than joint replacement. Importantly, chronic reductions in physical activity in patients with KOA may worsen pain, physical function, and exacerbate the metabolic consequences of obesity. Moreover, the greater mortality observed in symptomatic knee OA populations is likely mediated through its effect on physical activity. The current proposal aims to derive preliminary data to support a large pragmatic trial testing the impact of interventions geared towards improving physical activity and function in KOA patients.

Promoting physical activity has been shown to be helpful in reducing pain and improving function in KOA and other groups. However, promoting behavioral change in the arthritis population is a significant challenge. The group has shown that social incentives [and gamification] derived from concepts from the field of behavioral economics to promote behavioral change and increase physical activity can be both practical and effective in other settings. The investigators' group is studying incentives in patients with inflammatory arthritis with the goal of addressing fatigue, pain, and deficits in physical function. The incentivization of physical activity using this approach represents a novel intervention for the managing symptoms of KOA and to improving overall health.

Analgesic therapies can help KOA patients participate in exercise therapy. However, whether corticosteroid injections, a commonly used medical therapy for KOA pain, has a positive impact of physical activity is unknown and is an additional important question addressed by the current proposal. Despite widespread use, definitive data demonstrating a consistent benefit of corticosteroids are lacking. A large randomized trial recently tested the effects of repeated corticosteroids injections every 3 months for a period of 2 years on patient reported pain as well as progression of disease measured by magnetic resonance imaging (MRI). This study demonstrated no improvement in pain compared to saline injections. In addition, a small but statistically significant decline in cartilage thickness on MRI was observed, raising a concern for side effects. These recent data might suggest that corticosteroid injections result in more harm than good, and may discourage providers from performing this intervention. However, there are critical weaknesses to this study. Pain and function were only assessed at 3-month intervals, while previous trials have suggested that peak benefit is expected at 4-8 weeks. Moreover, the clinical and biologic significance decrease in cartilage thickness is unclear.

The investigators propose to fill these important knowledge gaps with an innovative and efficient pragmatic clinical trial with a factorial and crossover design. A large and definitive practical trial would lead to better understanding of the clinical effectiveness of these interventions, the meaningfulness of their combined impact, and the subgroups that are most likely to derive benefit. This clinical trial of 32-40 patients will leverage unique resources available through the Penn Center for Innovation to better capture important patient-reported outcomes in real-time through a web-based platform. The study will also test the feasibility of a crossover and factorial design to improve efficiency and reduce confounding. Each patient will receive each intervention (saline, corticosteroids) in random order over 1 year. A factorial design will be employed and will randomize participants to receive social incentives with gamification to promote increases in their physical activity. To accomplish these aims, the investigators will utilize innovative mobile applications for smart phones and wearable activity trackers through the Way-to-Health platform and assess, in real time, the impact of the intervention on patient-reported function and pain as well as physical activity. The technology will allow for the recording of outcomes as they occur, between clinic visits, thereby avoiding information bias due to poor recall. It will also provide real-time assessment of symptoms, providing granular assessments of response over time. The investigative team includes early career investigators with experience conducting similar trials using this infrastructure. Results will provide preliminary data to power a large, feasible, and low-cost pragmatic multi-site trial that would lead to practical implementation. The specific aims of the study are:

Aim 1: To determine the feasibility of recruitment and retention of Veterans with osteoarthritis of the knee (KOA) in a practical trial using an innovative online trial platform incorporating mobile activity monitors. The investigators expect to recruit and retain 32 Veterans within 1 year.

Study Design

Study Type:
Interventional
Actual Enrollment :
34 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Intervention Model Description:
Participants are randomized with a software application to receive social incentives to promote physical activity. They will also be randomized to receive corticosteroid injections in a crossover design.Participants are randomized with a software application to receive social incentives to promote physical activity. They will also be randomized to receive corticosteroid injections in a crossover design.
Masking:
Single (Participant)
Masking Description:
It is not possible to blind participants to the social incentives they will receive. For the injection aspect of the study, the investigator will be aware of the injection being given but the syringe will be covered to obscure the view of the patient.
Primary Purpose:
Treatment
Official Title:
A Pragmatic Trial to Determine the Benefit of Exercise Incentives and Corticosteroid Injections for Osteoarthritis of the Knee
Actual Study Start Date :
Jul 8, 2019
Actual Primary Completion Date :
May 1, 2021
Actual Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Social Incentives and Gamification, Corticosteroid AB

Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals. The participants will receive injections in A-B order (corticosteroids, then lidocaine only)

Behavioral: Social Incentives and Gamification to Promote Exercise
The intervention will provide social incentives and gamification to promote physical activity.

Procedure: Corticosteroid Injection given in A-B order
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.

Active Comparator: No Incentive, Corticosteroid AB

Participants will only receive reminders to sync their activity monitor. The participants will receive injections in A-B order (corticosteroids, then lidocaine only)

Procedure: Corticosteroid Injection given in A-B order
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.

Behavioral: No Social Incentive applied
No social incentive will be applied

Experimental: Social Incentives and Gamification, Corticosteroid BA

Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals. The participants will receive injections in B-A order (lidocaine only, then corticosteroids)

Behavioral: Social Incentives and Gamification to Promote Exercise
The intervention will provide social incentives and gamification to promote physical activity.

Procedure: Corticosteroid Injection given in B-A order
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.

Active Comparator: No Incentive, Corticosteroid BA

Participants will only receive reminders to sync their activity monitor. The participants will receive injections in B-A order (lidocaine only, then corticosteroids)

Behavioral: No Social Incentive applied
No social incentive will be applied

Procedure: Corticosteroid Injection given in B-A order
The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.

Outcome Measures

Primary Outcome Measures

  1. Percent change from baseline in weekly average steps per day [Measured weekly over 3-10 months]

    Steps measured by a wearable activity monitor

Secondary Outcome Measures

  1. Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) [Measured bi-weekly over 3-10 months]

    KOOS assessed by survey at 2 week intervals. KOOS scores range from 0 to 100 with 0 representing worse knee problems and 100 representing no knee problems.

  2. Change in PROMIS pain intensity score [Measured bi-weekly over 3-10 months]

    Assessed by survey at 2 week intervals. Scores range from 3-15 and are converted to T-Scores. A high score represents greater pain.

  3. Change in PROMIS Fatigue [Measured every 4 weeks over 3-10 months]

    Assessed by survey at 4 week intervals

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Veterans in VA Rheumatology or Orthopedic clinics

  • Chronic knee osteoarthritis

  • Indication for joint injection

  • Previous joint injections for palliation

  • Patient expresses interest in increasing their physical activity

  • Patient is able to walk 1/2 mile per day

Exclusion Criteria:
  • Intra-articular hardware or other contraindication to joint injection

  • Lack of smart phone

  • Acute exacerbation of osteoarthritis or knee pain

  • Unable or unwilling to identify a social sponsor

  • Comorbid condition that precludes safe exercise

Contacts and Locations

Locations

Site City State Country Postal Code
1 Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • VA Office of Research and Development

Investigators

  • Principal Investigator: Joshua F. Baker, MD MSCE, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT03835910
Other Study ID Numbers:
  • F3157-P
First Posted:
Feb 11, 2019
Last Update Posted:
Jul 27, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2021